97 related articles for article (PubMed ID: 27552486)
1. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
2. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
3. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
4. Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme.
Stoyanova A; Galabov AS
Arch Virol; 2021 Jul; 166(7):1869-1875. PubMed ID: 33877422
[TBL] [Abstract][Full Text] [Related]
5. Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3.
Stoyanova A; Galabov AS
Pathog Dis; 2020 Nov; 78(9):. PubMed ID: 33090201
[TBL] [Abstract][Full Text] [Related]
6. Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice.
Grozdanov P; Joffret ML; Stoyanova A; Polston P; Achouri E; Nikolova I; Delpeyroux F; Galabov AS
Antivir Chem Chemother; 2020; 28():2040206620906061. PubMed ID: 32041425
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
8. Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice.
Vassileva-Pencheva R; Galabov AS
Antiviral Res; 2010 Feb; 85(2):366-72. PubMed ID: 19900482
[TBL] [Abstract][Full Text] [Related]
9. Effects of double combinations of enterovirus replication inhibitors against Coxsackie B viruses.
Stoyanova A; Galabov AS
Acta Virol; 2021; 65(4):411-419. PubMed ID: 34978843
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
Nikolaeva L; Galabov AS
Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
[TBL] [Abstract][Full Text] [Related]
11. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations.
Pauksen K; Ilbäck NG; Friman G; Fohlman J
Scand J Infect Dis Suppl; 1993; 88():125-30. PubMed ID: 8390715
[TBL] [Abstract][Full Text] [Related]
12. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice.
Nikolova I; Galabov AS
Antiviral Res; 2003 Sep; 60(1):35-40. PubMed ID: 14516919
[TBL] [Abstract][Full Text] [Related]
13.
Lee YG; Park JH; Jeon ES; Kim JH; Lim BK
J Microbiol Biotechnol; 2016 Nov; 26(11):2012-2018. PubMed ID: 27558433
[TBL] [Abstract][Full Text] [Related]
14. QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3.
Muratov EN; Varlamova EV; Artemenko AG; Khristova T; Kuz'min VE; Makarov VA; Riabova OB; Wutzler P; Schmidtke M
Future Med Chem; 2011 Jan; 3(1):15-27. PubMed ID: 21428823
[TBL] [Abstract][Full Text] [Related]
15. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of WIN 54954 in coxsackievirus B2 carrier state infected human myocardial fibroblasts.
Heim A; Pfetzing U; Müller G; Grumbach IM
Antiviral Res; 1998 Jan; 37(1):47-56. PubMed ID: 9497072
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide influences viral replication in target organs of coxsackievirus B3-infected mice.
Molin Y; Frisk P; Hjelm E; Blomberg J; Friman G; Ilbäck NG
Microbes Infect; 2010 Nov; 12(12-13):1027-34. PubMed ID: 20638482
[TBL] [Abstract][Full Text] [Related]
18. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Chinese herbal medicine Xin-kang oral liquid on interferon-induction and its antiviral activity in coxsackievirus B3 infected mice].
Wan SJ; Li JN; Zhao H; Wang LX; Huang XZ; Zhu Y; Chen HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):77-9. PubMed ID: 16201482
[TBL] [Abstract][Full Text] [Related]
20. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]